Celularity Inc
NASDAQ:CELU
Celularity Inc
NASDAQ:CELU
Price:
1.22
USD
1.67%
Market Cap:
$35.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Celularity Inc
NASDAQ:CELU
|
US |
|
American Defense Systems Inc
OTC:ADFS
|
US |
|
GoodWe Technologies Co Ltd
SSE:688390
|
CN |
|
Shanghai Guao Electronic Technology Co Ltd
SZSE:300551
|
CN |
|
Masterwork Group Co Ltd
SZSE:300195
|
CN |
|
Banco Products (India) Ltd
NSE:BANCOINDIA
|
IN |
|
Shenwan Hongyuan Group Co Ltd
SZSE:000166
|
CN |
|
C
|
Chaosua Foods Industry PCL
SET:CHAO
|
TH |
|
J
|
JY Grandmark Holdings Ltd
HKEX:2231
|
CN |
|
PB Fintech Ltd
NSE:POLICYBZR
|
IN |
|
S
|
Sharetronic Data Technology Co Ltd
SZSE:300857
|
CN |
|
Snam SpA
MIL:SRG
|
IT |
|
Lanxess AG
XETRA:LXS
|
DE |
|
Webstep ASA
OSE:WSTEP
|
NO |
|
China Xuefeng Environmental Engineering Inc
OTC:ELEK
|
CN |
|
C
|
Choom Holdings Inc
CNSX:CHOO
|
CA |
|
Hubei Feilihua Quartz Glass Co Ltd
SZSE:300395
|
CN |
|
Keerti Knowledge and Skills Ltd
NSE:KEERTI
|
IN |
|
B
|
Big Technologies PLC
LSE:BIG
|
UK |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
US |
|
G
|
Gentili Mosconi SpA
MIL:GM
|
IT |
|
S
|
Sichuan Lutianhua Co Ltd
SZSE:000912
|
CN |
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
CN |
|
John B Sanfilippo & Son Inc
NASDAQ:JBSS
|
US |
Balance Sheet
Balance Sheet Decomposition
Celularity Inc
Celularity Inc
Balance Sheet Decomposition is not available for
Celularity Inc
Celularity Inc
Balance Sheet
Celularity Inc
Celularity Inc
Currency: USD
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
0
|
1
|
0
|
37
|
14
|
0
|
0
|
|
| Cash |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
37
|
14
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
5
|
7
|
12
|
14
|
|
| Accounts Receivables |
0
|
0
|
0
|
5
|
9
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
2
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
10
|
5
|
6
|
5
|
|
| Other Current Assets |
0
|
0
|
0
|
7
|
7
|
2
|
1
|
|
| Total Current Assets |
0
|
1
|
0
|
59
|
34
|
20
|
21
|
|
| PP&E Net |
0
|
0
|
0
|
91
|
89
|
79
|
72
|
|
| PP&E Gross |
0
|
0
|
0
|
91
|
89
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
15
|
20
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
123
|
121
|
11
|
9
|
|
| Goodwill |
0
|
0
|
0
|
123
|
120
|
7
|
7
|
|
| Long-Term Investments |
0
|
291
|
292
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
18
|
38
|
17
|
13
|
|
| Other Assets |
0
|
0
|
0
|
123
|
120
|
7
|
7
|
|
| Total Assets |
0
N/A
|
292
+167 489%
|
292
+0%
|
414
+42%
|
401
-3%
|
144
-64%
|
133
-8%
|
|
| Liabilities | ||||||||
| Accounts Payable |
0
|
0
|
3
|
9
|
6
|
14
|
23
|
|
| Accrued Liabilities |
0
|
0
|
0
|
7
|
14
|
9
|
19
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
38
|
39
|
6
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
3
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
7
|
5
|
5
|
5
|
|
| Total Current Liabilities |
0
|
0
|
3
|
26
|
62
|
67
|
54
|
|
| Long-Term Debt |
0
|
0
|
0
|
28
|
0
|
0
|
36
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
11
|
11
|
260
|
140
|
36
|
34
|
|
| Total Liabilities |
0
N/A
|
11
+7 213%
|
14
+29%
|
315
+2 113%
|
202
-36%
|
103
-49%
|
124
+20%
|
|
| Equity | ||||||||
| Common Stock |
0
|
276
|
273
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
0
|
3
|
0
|
664
|
645
|
842
|
900
|
|
| Additional Paid In Capital |
0
|
2
|
5
|
763
|
844
|
883
|
909
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
0
N/A
|
281
+1 168 917%
|
278
-1%
|
99
-64%
|
199
+100%
|
41
-79%
|
9
-78%
|
|
| Total Liabilities & Equity |
0
N/A
|
292
+167 489%
|
292
+0%
|
414
+42%
|
401
-3%
|
144
-64%
|
133
-8%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
9
|
10
|
10
|
12
|
15
|
19
|
23
|
|
Switch to:
Switch to:
See Also
Discover More
